Obstetrics – Preeclampsia
Conditions
Brief summary
To assess whether ASA discontinuation at 24–26 weeks is non-inferior in preventing preterm PE compared with the control group, who will continue ASA until 36 weeks.
Detailed description
To assess whether ASA discontinuation does not increase maternal, fetal, or neonatal morbidity or mortality., To assess whether ASA discontinuation discontinuing aspirin treatment reduces the risk of maternal hemorrhage
Interventions
DRUGACETYLSALICYLIC ACID
Sponsors
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess whether ASA discontinuation at 24–26 weeks is non-inferior in preventing preterm PE compared with the control group, who will continue ASA until 36 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess whether ASA discontinuation does not increase maternal, fetal, or neonatal morbidity or mortality., To assess whether ASA discontinuation discontinuing aspirin treatment reduces the risk of maternal hemorrhage | — |
Outcome results
None listed